BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 15365064)

  • 1. Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma.
    Lee JH; Essner R; Torisu-Itakura H; Wanek L; Wang H; Morton DL
    J Clin Oncol; 2004 Sep; 22(18):3677-84. PubMed ID: 15365064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of nonsentinel lymph node positivity in patients with a positive sentinel node for melanoma.
    Sabel MS; Griffith K; Sondak VK; Lowe L; Schwartz JL; Cimmino VM; Chang AE; Rees RS; Bradford CR; Johnson TM
    J Am Coll Surg; 2005 Jul; 201(1):37-47. PubMed ID: 15978442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of a new scoring system for predicting non-sentinel node positivity in sentinel node-positive melanoma patients.
    Wevers KP; Murali R; Bastiaannet E; Scolyer RA; Suurmeijer AJ; Thompson JF; Hoekstra HJ
    Eur J Surg Oncol; 2013 Feb; 39(2):179-84. PubMed ID: 23137997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2-pT3).
    Nowecki ZI; Rutkowski P; Michej W
    Ann Surg Oncol; 2008 Aug; 15(8):2223-34. PubMed ID: 18506535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of nonsentinel lymph node involvement in patients with a positive sentinel lymph node in malignant melanoma.
    Page AJ; Carlson GW; Delman KA; Murray D; Hestley A; Cohen C
    Am Surg; 2007 Jul; 73(7):674-8; discussion 678-9. PubMed ID: 17674939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do micromorphometric features of metastatic deposits within sentinel nodes predict nonsentinel lymph node involvement in melanoma?
    Frankel TL; Griffith KA; Lowe L; Wong SL; Bichakjian CK; Chang AE; Cimmino VM; Bradford CR; Rees RS; Johnson TM; Sabel MS
    Ann Surg Oncol; 2008 Sep; 15(9):2403-11. PubMed ID: 18626721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High positive sentinel node identification rate by EORTC melanoma group protocol. Prognostic indicators of metastatic patterns after sentinel node biopsy in melanoma.
    van Akkooi AC; de Wilt JH; Verhoef C; Graveland WJ; van Geel AN; Kliffen M; Eggermont AM
    Eur J Cancer; 2006 Feb; 42(3):372-80. PubMed ID: 16403622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of non-sentinel node status and outcome in sentinel node-positive melanoma patients.
    Roka F; Mastan P; Binder M; Okamoto I; Mittlboeck M; Horvat R; Pehamberger H; Diem E
    Eur J Surg Oncol; 2008 Jan; 34(1):82-8. PubMed ID: 17360144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isolated tumor cells in the sentinel node affect long-term prognosis of patients with melanoma.
    Scheri RP; Essner R; Turner RR; Ye X; Morton DL
    Ann Surg Oncol; 2007 Oct; 14(10):2861-6. PubMed ID: 17882497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: a multicenter study in 388 patients with positive sentinel nodes.
    van Akkooi AC; Nowecki ZI; Voit C; Schäfer-Hesterberg G; Michej W; de Wilt JH; Rutkowski P; Verhoef C; Eggermont AM
    Ann Surg; 2008 Dec; 248(6):949-55. PubMed ID: 19092339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multivariable analysis comparing outcome after sentinel node biopsy or therapeutic lymph node dissection in patients with melanoma.
    van Akkooi AC; Bouwhuis MG; de Wilt JH; Kliffen M; Schmitz PI; Eggermont AM
    Br J Surg; 2007 Oct; 94(10):1293-9. PubMed ID: 17702089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival analysis and clinicopathological factors associated with false-negative sentinel lymph node biopsy findings in patients with cutaneous melanoma.
    Nowecki ZI; Rutkowski P; Nasierowska-Guttmejer A; Ruka W
    Ann Surg Oncol; 2006 Dec; 13(12):1655-63. PubMed ID: 17016755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sentinel lymph node biopsy in melanoma: a micromorphometric study relating to prognosis and completion lymph node dissection.
    Debarbieux S; Duru G; Dalle S; Béatrix O; Balme B; Thomas L
    Br J Dermatol; 2007 Jul; 157(1):58-67. PubMed ID: 17501957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histological features of melanoma sentinel lymph node metastases associated with status of the completion lymphadenectomy and rate of subsequent relapse.
    Govindarajan A; Ghazarian DM; McCready DR; Leong WL
    Ann Surg Oncol; 2007 Feb; 14(2):906-12. PubMed ID: 17136471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indications for lymphatic mapping and sentinel lymphadenectomy in patients with thin melanoma (Breslow thickness < or =1.0 mm).
    Stitzenberg KB; Groben PA; Stern SL; Thomas NE; Hensing TA; Sansbury LB; Ollila DW
    Ann Surg Oncol; 2004 Oct; 11(10):900-6. PubMed ID: 15383424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of sentinel node biopsy in 327 prospective melanoma patients from a single institution.
    Roulin D; Matter M; Bady P; Liénard D; Gugerli O; Boubaker A; Bron L; Lejeune FJ
    Eur J Surg Oncol; 2008 Jun; 34(6):673-9. PubMed ID: 17825518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re-evaluation of a scoring system to predict nonsentinel-node metastasis and prognosis in melanoma patients.
    Cadili A; Dabbs K; Scolyer RA; Brown PT; Thompson JF
    J Am Coll Surg; 2010 Oct; 211(4):522-5. PubMed ID: 20729103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors predictive of nonsentinel lymph node involvement and clinical outcome in melanoma patients with metastatic sentinel lymph node.
    Rossi CR; De Salvo GL; Bonandini E; Mocellin S; Foletto M; Pasquali S; Pilati P; Lise M; Nitti D; Rizzo E; Montesco MC
    Ann Surg Oncol; 2008 Apr; 15(4):1202-10. PubMed ID: 18165880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
    Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W
    Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EORTC Melanoma Group sentinel node protocol identifies high rate of submicrometastases according to Rotterdam Criteria.
    van der Ploeg AP; van Akkooi AC; Schmitz PI; Koljenovic S; Verhoef C; Eggermont AM
    Eur J Cancer; 2010 Sep; 46(13):2414-21. PubMed ID: 20621467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.